STOCK TITAN

Cyclerion Therapeutics Inc SEC Filings

CYCN NASDAQ

Welcome to our dedicated page for Cyclerion Therapeutics SEC filings (Ticker: CYCN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading a clinical-stage biotech filing can feel like decoding a lab notebook. Cyclerion Therapeutics packs pages of sGC pharmacology data, trial protocols, and milestone royalty terms into every document, making it hard to spot cash-runway risks or FDA-related 8-K updates.

Stock Titan removes that barrier. Our AI engine parses each Cyclerion filing the moment it hits EDGAR, then delivers plain-English highlights—whether you’re skimming the Cyclerion Therapeutics quarterly earnings report 10-Q filing for R&D spend, or need Cyclerion insider trading Form 4 transactions in real time. Investors can instantly compare segments, track Cyclerion executive stock transactions Form 4, or dive into a Cyclerion annual report 10-K simplified summary without wading through clinical jargon.

Every document type is covered: 8-K material events explained when trial data drop, proxy statement executive compensation details for governance checks, and Form S-3 shelves that fund future studies. Use cases include:

  • Flagging Cyclerion Form 4 insider transactions real-time before catalysts
  • Monitoring trial-cost trends via our Cyclerion earnings report filing analysis
  • Understanding Cyclerion SEC documents with AI to gauge licensing revenue potential
Stop hunting through dense PDFs. With AI-powered summaries, expert context, and alerts delivered the minute Cyclerion files, you’ll always know when a CNS program progresses, how much R&D cash is left, and why a particular 8-K matters—Cyclerion SEC filings explained simply.

Rhea-AI Summary

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) filed a Current Report on Form 8-K disclosing the formal voting results from its 16 June 2025 Annual Meeting of Shareholders.

  • Election of directors: All six nominees—Errol De Souza, Regina Graul, Peter M. Hecht, Steven Hyman, Michael Higgins and Dina Katabi—were re-elected, each receiving roughly 1.32–1.34 million votes FOR versus 63–73 thousand AGAINST; 743,285 broker non-votes were recorded.
  • Auditor ratification: Ernst & Young LLP was confirmed for fiscal 2025 with 2,072,684 FOR, 57,547 AGAINST and 147 ABSTAIN.
  • Say-on-pay (advisory): Executive compensation passed (1,312,697 FOR; 78,221 AGAINST; 6,203 ABSTAIN).
  • Say-on-pay frequency: Shareholders favored an annual vote (827,809 one-year vs. 562,965 three-year).
  • Adjournment authority: The option to adjourn, if necessary, also passed (2,036,703 FOR; 84,719 AGAINST; 18,984 ABSTAIN).

The filing is procedural, reinforces existing governance structures and contains no new financial, operational or strategic disclosures likely to affect the company’s near-term outlook.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Cyclerion Therapeutics (CYCN)?

The current stock price of Cyclerion Therapeutics (CYCN) is $3.6399 as of July 11, 2025.

What is the market cap of Cyclerion Therapeutics (CYCN)?

The market cap of Cyclerion Therapeutics (CYCN) is approximately 12.0M.

What is Cyclerion Therapeutics Inc's primary focus?

Cyclerion is dedicated to leveraging sGC pharmacology to develop innovative treatments for serious and orphan diseases, addressing significant unmet medical needs.

How does the company advance its product pipeline?

The company employs a rigorous clinical stage process, advancing multiple candidates through phases of clinical evaluation, while focusing on both vascular and central nervous system indications.

What role do strategic partnerships play in Cyclerion's business model?

Strategic partnerships, including licensing agreements, help the company monetize legacy assets and provide capital for reinvestment into its evolving pipeline, thereby supporting its clinical development efforts.

Which therapeutic areas are targeted by Cyclerion's product candidates?

Cyclerion is focused on several key areas, including conditions related to vascular dysfunction and neurodegenerative disorders, alongside chronic diseases such as sickle cell disease and heart failure.

How does Cyclerion differentiate itself from competitors?

Its unique approach, centered on advanced sGC stimulation, coupled with methodical clinical evaluations and strategic licensing, sets it apart in the realm of clinical-stage biopharmaceutical companies.

What is the importance of sGC stimulation in their therapeutic strategy?

sGC stimulation plays a critical role in enhancing vascular function and modulating central nervous system pathways, providing a novel avenue to address complex and multifactorial diseases.

How does Cyclerion manage the commercialization aspects of its products?

The company utilizes a balanced strategy by partnering with external entities for licensing and royalty-based agreements, thereby facilitating a cost-effective approach to commercialization without overextending resources.

What should investors understand about Cyclerion’s market position?

Investors should note that Cyclerion is a research-intensive entity with a clear focus on deep scientific inquiry and clinical precision, underscored by strategic monetization efforts and robust partner collaborations.
Cyclerion Therapeutics Inc

NASDAQ:CYCN

CYCN Rankings

CYCN Stock Data

11.96M
2.11M
26.81%
16.03%
4.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE